XML 72 R51.htm IDEA: XBRL DOCUMENT
v3.23.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Apr. 02, 2023 | Apr. 03, 2022
Sales by segment of business |  |
Sales to customers | $ 24,746 | $ 23,426
Percent Change (as a percent) | 5.60% |
U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 12,517 | 11,414
Percent Change (as a percent) | 9.70% |
International |  |
Sales by segment of business |  |
Sales to customers | $ 12,229 | 12,012
Percent Change (as a percent) | 1.80% |
CONSUMER HEALTH |  |
Sales by segment of business |  |
Sales to customers | $ 3,852 | 3,586
Percent Change (as a percent) | 7.40% |
CONSUMER HEALTH | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,735 | 1,557
Percent Change (as a percent) | 11.40% |
CONSUMER HEALTH | International |  |
Sales by segment of business |  |
Sales to customers | $ 2,117 | 2,029
Percent Change (as a percent) | 4.40% |
CONSUMER HEALTH | OTC [Member] |  |
Sales by segment of business |  |
Sales to customers | $ 1,642 | 1,461
Percent Change (as a percent) | 12.40% |
CONSUMER HEALTH | OTC [Member] | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 745 | 670
Percent Change (as a percent) | 11.00% |
CONSUMER HEALTH | OTC [Member] | International |  |
Sales by segment of business |  |
Sales to customers | $ 897 | 791
Percent Change (as a percent) | 13.50% |
CONSUMER HEALTH | Skin Health/Beauty |  |
Sales by segment of business |  |
Sales to customers | $ 1,110 | 1,012
Percent Change (as a percent) | 9.70% |
CONSUMER HEALTH | Skin Health/Beauty | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 617 | 544
Percent Change (as a percent) | 13.40% |
CONSUMER HEALTH | Skin Health/Beauty | International |  |
Sales by segment of business |  |
Sales to customers | $ 493 | 468
Percent Change (as a percent) | 5.30% |
CONSUMER HEALTH | Oral Care |  |
Sales by segment of business |  |
Sales to customers | $ 361 | 366
Percent Change (as a percent) | (1.30%) |
CONSUMER HEALTH | Oral Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 159 | 143
Percent Change (as a percent) | 11.60% |
CONSUMER HEALTH | Oral Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 202 | 223
Percent Change (as a percent) | (9.60%) |
CONSUMER HEALTH | Baby Care |  |
Sales by segment of business |  |
Sales to customers | $ 359 | 355
Percent Change (as a percent) | 1.00% |
CONSUMER HEALTH | Baby Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 96 | 85
Percent Change (as a percent) | 13.00% |
CONSUMER HEALTH | Baby Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 263 | 270
Percent Change (as a percent) | (2.80%) |
CONSUMER HEALTH | Women’s Health |  |
Sales by segment of business |  |
Sales to customers | $ 217 | 228
Percent Change (as a percent) | (4.80%) |
CONSUMER HEALTH | Women’s Health | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 3
Percent Change (as a percent) | 1.80% |
CONSUMER HEALTH | Women’s Health | International |  |
Sales by segment of business |  |
Sales to customers | $ 214 | 224
Percent Change (as a percent) | (4.90%) |
CONSUMER HEALTH | Wound Care/Other |  |
Sales by segment of business |  |
Sales to customers | $ 164 | 164
Percent Change (as a percent) | (0.10%) |
CONSUMER HEALTH | Wound Care/Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 115 | 112
Percent Change (as a percent) | 2.60% |
CONSUMER HEALTH | Wound Care/Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 49 | 52
Percent Change (as a percent) | (6.00%) |
PHARMACEUTICAL |  |
Sales by segment of business |  |
Sales to customers | $ 13,413 | 12,869
Percent Change (as a percent) | 4.20% |
PHARMACEUTICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 7,023 | 6,632
Percent Change (as a percent) | 5.90% |
PHARMACEUTICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 6,390 | 6,237
Percent Change (as a percent) | 2.40% |
PHARMACEUTICAL | Immunology |  |
Sales by segment of business |  |
Sales to customers | $ 4,112 | 4,119
Percent Change (as a percent) | (0.20%) |
PHARMACEUTICAL | Immunology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2,448 | 2,501
Percent Change (as a percent) | (2.10%) |
PHARMACEUTICAL | Immunology | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,664 | 1,617
Percent Change (as a percent) | 2.90% |
PHARMACEUTICAL | Immunology | REMICADE |  |
Sales by segment of business |  |
Sales to customers | $ 487 | 663
Percent Change (as a percent) | (26.50%) |
PHARMACEUTICAL | Immunology | REMICADE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 276 | 358
Percent Change (as a percent) | (22.80%) |
PHARMACEUTICAL | Immunology | REMICADE | U.S. Exports |  |
Sales by segment of business |  |
Sales to customers | $ 41 | 80
Percent Change (as a percent) | (48.80%) |
PHARMACEUTICAL | Immunology | REMICADE | International |  |
Sales by segment of business |  |
Sales to customers | $ 170 | 225
Percent Change (as a percent) | (24.40%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA |  |
Sales by segment of business |  |
Sales to customers | $ 537 | 571
Percent Change (as a percent) | (5.80%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 271 | 287
Percent Change (as a percent) | (5.60%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | International |  |
Sales by segment of business |  |
Sales to customers | $ 266 | 283
Percent Change (as a percent) | (6.10%) |
PHARMACEUTICAL | Immunology | STELARA |  |
Sales by segment of business |  |
Sales to customers | $ 2,444 | 2,288
Percent Change (as a percent) | 6.80% |
PHARMACEUTICAL | Immunology | STELARA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,451 | 1,379
Percent Change (as a percent) | 5.20% |
PHARMACEUTICAL | Immunology | STELARA | International |  |
Sales by segment of business |  |
Sales to customers | $ 993 | 909
Percent Change (as a percent) | 9.30% |
PHARMACEUTICAL | Immunology | TREMFYA |  |
Sales by segment of business |  |
Sales to customers | $ 640 | 590
Percent Change (as a percent) | 8.40% |
PHARMACEUTICAL | Immunology | TREMFYA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 406 | 391
Percent Change (as a percent) | 3.90% |
PHARMACEUTICAL | Immunology | TREMFYA | International |  |
Sales by segment of business |  |
Sales to customers | $ 234 | 199
Percent Change (as a percent) | 17.30% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 6
Percent Change (as a percent) | (51.30%) |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 6
Percent Change (as a percent) | (51.20%) |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Infectious Diseases |  |
Sales by segment of business |  |
Sales to customers | $ 1,586 | 1,297
Percent Change (as a percent) | 22.30% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 392 | 461
Percent Change (as a percent) | (14.90%) |
PHARMACEUTICAL | Infectious Diseases | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,193 | 836
Percent Change (as a percent) | 42.80% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 |  |
Sales by segment of business |  |
Sales to customers | $ 747 | 457
Percent Change (as a percent) | 63.40% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 75
PHARMACEUTICAL | Infectious Diseases | COVID-19 | International |  |
Sales by segment of business |  |
Sales to customers | $ 747 | 382
Percent Change (as a percent) | 95.60% |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine |  |
Sales by segment of business |  |
Sales to customers | $ 280 | 248
Percent Change (as a percent) | 12.80% |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 9 | 9
Percent Change (as a percent) | (1.40%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | International |  |
Sales by segment of business |  |
Sales to customers | $ 271 | 239
Percent Change (as a percent) | 13.40% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |
Sales by segment of business |  |
Sales to customers | $ 477 | 501
Percent Change (as a percent) | (4.80%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 378 | 369
Percent Change (as a percent) | 2.50% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |
Sales by segment of business |  |
Sales to customers | $ 99 | 132
Percent Change (as a percent) | (25.20%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |
Sales by segment of business |  |
Sales to customers | $ 82 | 91
Percent Change (as a percent) | (9.80%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 5 | 8
Percent Change (as a percent) | (33.10%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |
Sales by segment of business |  |
Sales to customers | $ 77 | 83
Percent Change (as a percent) | (7.60%) |
PHARMACEUTICAL | Neuroscience |  |
Sales by segment of business |  |
Sales to customers | $ 1,804 | 1,741
Percent Change (as a percent) | 3.60% |
PHARMACEUTICAL | Neuroscience | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 978 | 843
Percent Change (as a percent) | 16.00% |
PHARMACEUTICAL | Neuroscience | International |  |
Sales by segment of business |  |
Sales to customers | $ 826 | 898
Percent Change (as a percent) | (8.10%) |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate |  |
Sales by segment of business |  |
Sales to customers | $ 206 | 157
Percent Change (as a percent) | 31.40% |
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 70 | 35
PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | International |  |
Sales by segment of business |  |
Sales to customers | $ 136 | 122
Percent Change (as a percent) | 11.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |
Sales by segment of business |  |
Sales to customers | $ 1,044 | 1,048
Percent Change (as a percent) | (0.40%) |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 713 | 661
Percent Change (as a percent) | 7.90% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |
Sales by segment of business |  |
Sales to customers | $ 331 | 387
Percent Change (as a percent) | (14.60%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |
Sales by segment of business |  |
Sales to customers | $ 423 | 467
Percent Change (as a percent) | (9.40%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 84 | 86
Percent Change (as a percent) | (3.50%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |
Sales by segment of business |  |
Sales to customers | $ 339 | 380
Percent Change (as a percent) | (10.70%) |
PHARMACEUTICAL | Neuroscience | SPRAVATO |  |
Sales by segment of business |  |
Sales to customers | $ 131 | 70
Percent Change (as a percent) | 86.90% |
PHARMACEUTICAL | Neuroscience | SPRAVATO | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 111 | 61
Percent Change (as a percent) | 82.40% |
PHARMACEUTICAL | Neuroscience | SPRAVATO | International |  |
Sales by segment of business |  |
Sales to customers | $ 20 | 9
PHARMACEUTICAL | Oncology |  |
Sales by segment of business |  |
Sales to customers | $ 4,112 | 3,950
Percent Change (as a percent) | 4.10% |
PHARMACEUTICAL | Oncology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,889 | 1,582
Percent Change (as a percent) | 19.40% |
PHARMACEUTICAL | Oncology | International |  |
Sales by segment of business |  |
Sales to customers | $ 2,223 | 2,369
Percent Change (as a percent) | (6.10%) |
PHARMACEUTICAL | Oncology | DARZALEX |  |
Sales by segment of business |  |
Sales to customers | $ 2,264 | 1,856
Percent Change (as a percent) | 22.00% |
PHARMACEUTICAL | Oncology | DARZALEX | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,191 | 953
Percent Change (as a percent) | 25.00% |
PHARMACEUTICAL | Oncology | DARZALEX | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,072 | 903
Percent Change (as a percent) | 18.80% |
PHARMACEUTICAL | Oncology | ERLEADA |  |
Sales by segment of business |  |
Sales to customers | $ 542 | 400
Percent Change (as a percent) | 35.60% |
PHARMACEUTICAL | Oncology | ERLEADA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 249 | 206
Percent Change (as a percent) | 21.20% |
PHARMACEUTICAL | Oncology | ERLEADA | International |  |
Sales by segment of business |  |
Sales to customers | $ 293 | 194
Percent Change (as a percent) | 50.90% |
PHARMACEUTICAL | Oncology | IMBRUVICA |  |
Sales by segment of business |  |
Sales to customers | $ 827 | 1,038
Percent Change (as a percent) | (20.30%) |
PHARMACEUTICAL | Oncology | IMBRUVICA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 270 | 370
Percent Change (as a percent) | (27.10%) |
PHARMACEUTICAL | Oncology | IMBRUVICA | International |  |
Sales by segment of business |  |
Sales to customers | $ 557 | 668
Percent Change (as a percent) | (16.60%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate |  |
Sales by segment of business |  |
Sales to customers | $ 245 | 539
Percent Change (as a percent) | (54.50%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 16 | 19
Percent Change (as a percent) | (14.00%) |
PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | International |  |
Sales by segment of business |  |
Sales to customers | $ 229 | 520
Percent Change (as a percent) | (56.00%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 162 | 118
Percent Change (as a percent) | 37.40% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 92 | 34
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 70 | 84
Percent Change (as a percent) | (17.20%) |
PHARMACEUTICAL | Oncology | CARVYKTI |  |
Sales by segment of business |  |
Sales to customers | $ 72 | 0
PHARMACEUTICAL | Oncology | CARVYKTI | U.S. |  |
Sales by segment of business |  |
Sales to customers | 70 | 0
PHARMACEUTICAL | Oncology | CARVYKTI | International |  |
Sales by segment of business |  |
Sales to customers | 2 | 0
PHARMACEUTICAL | Pulmonary Hypertension |  |
Sales by segment of business |  |
Sales to customers | $ 872 | 852
Percent Change (as a percent) | 2.40% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 600 | 572
Percent Change (as a percent) | 4.90% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |
Sales by segment of business |  |
Sales to customers | $ 272 | 279
Percent Change (as a percent) | (2.70%) |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT |  |
Sales by segment of business |  |
Sales to customers | $ 440 | 443
Percent Change (as a percent) | (0.70%) |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 273 | 273
Percent Change (as a percent) | (0.10%) |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | International |  |
Sales by segment of business |  |
Sales to customers | $ 167 | 170
Percent Change (as a percent) | (1.60%) |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI |  |
Sales by segment of business |  |
Sales to customers | $ 362 | 325
Percent Change (as a percent) | 11.40% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 304 | 269
Percent Change (as a percent) | 13.10% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | International |  |
Sales by segment of business |  |
Sales to customers | $ 58 | 56
Percent Change (as a percent) | 3.30% |
PHARMACEUTICAL | Pulmonary Hypertension | Other |  |
Sales by segment of business |  |
Sales to customers | $ 70 | 83
Percent Change (as a percent) | (16.10%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 23 | 30
Percent Change (as a percent) | (22.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 47 | 53
Percent Change (as a percent) | (12.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |
Sales by segment of business |  |
Sales to customers | $ 927 | 910
Percent Change (as a percent) | 1.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 715 | 672
Percent Change (as a percent) | 6.30% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 212 | 238
Percent Change (as a percent) | (10.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO |  |
Sales by segment of business |  |
Sales to customers | $ 578 | 508
Percent Change (as a percent) | 13.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 578 | 508
Percent Change (as a percent) | 13.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other |  |
Sales by segment of business |  |
Sales to customers | $ 349 | 402
Percent Change (as a percent) | (13.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 137 | 164
Percent Change (as a percent) | (16.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 212 | 238
Percent Change (as a percent) | (10.80%) |
MEDTECH |  |
Sales by segment of business |  |
Sales to customers | $ 7,481 | 6,971
Percent Change (as a percent) | 7.30% |
MEDTECH | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3,759 | 3,225
Percent Change (as a percent) | 16.60% |
MEDTECH | International |  |
Sales by segment of business |  |
Sales to customers | $ 3,722 | 3,746
Percent Change (as a percent) | (0.60%) |
MEDTECH | Interventional Solutions |  |
Sales by segment of business |  |
Sales to customers | $ 1,503 | 1,092
Percent Change (as a percent) | 37.60% |
MEDTECH | Interventional Solutions | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 863 | 494
Percent Change (as a percent) | 74.50% |
MEDTECH | Interventional Solutions | International |  |
Sales by segment of business |  |
Sales to customers | $ 640 | 597
Percent Change (as a percent) | 7.10% |
MEDTECH | ELECTROPHYSIOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 1,092 | 1,002
Percent Change (as a percent) | 9.10% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 571 | 470
Percent Change (as a percent) | 21.40% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 522 | 532
Percent Change (as a percent) | (1.80%) |
MEDTECH | ABIOMED(3) |  |
Sales by segment of business |  |
Sales to customers | $ 324 | 0
MEDTECH | ABIOMED(3) | U.S. |  |
Sales by segment of business |  |
Sales to customers | 264 | 0
MEDTECH | ABIOMED(3) | International |  |
Sales by segment of business |  |
Sales to customers | 60 | 0
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS |  |
Sales by segment of business |  |
Sales to customers | $ 87 | 90
Percent Change (as a percent) | (3.90%) |
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 28 | 24
Percent Change (as a percent) | 17.40% |
MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | International |  |
Sales by segment of business |  |
Sales to customers | $ 58 | 65
Percent Change (as a percent) | (11.70%) |
MEDTECH | Orthopaedics |  |
Sales by segment of business |  |
Sales to customers | $ 2,245 | 2,188
Percent Change (as a percent) | 2.60% |
MEDTECH | Orthopaedics | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,363 | 1,289
Percent Change (as a percent) | 5.80% |
MEDTECH | Orthopaedics | International |  |
Sales by segment of business |  |
Sales to customers | $ 881 | 899
Percent Change (as a percent) | (2.00%) |
MEDTECH | Orthopaedics | HIPS |  |
Sales by segment of business |  |
Sales to customers | $ 390 | 389
Percent Change (as a percent) | 0.40% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 241 | 225
Percent Change (as a percent) | 7.30% |
MEDTECH | Orthopaedics | HIPS | International |  |
Sales by segment of business |  |
Sales to customers | $ 149 | 164
Percent Change (as a percent) | (9.00%) |
MEDTECH | Orthopaedics | KNEES |  |
Sales by segment of business |  |
Sales to customers | $ 368 | 339
Percent Change (as a percent) | 8.70% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 226 | 201
Percent Change (as a percent) | 12.40% |
MEDTECH | Orthopaedics | KNEES | International |  |
Sales by segment of business |  |
Sales to customers | $ 142 | 138
Percent Change (as a percent) | 3.40% |
MEDTECH | Orthopaedics | TRAUMA |  |
Sales by segment of business |  |
Sales to customers | $ 757 | 748
Percent Change (as a percent) | 1.20% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 491 | 475
Percent Change (as a percent) | 3.20% |
MEDTECH | Orthopaedics | TRAUMA | International |  |
Sales by segment of business |  |
Sales to customers | $ 267 | 273
Percent Change (as a percent) | (2.40%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 729 | 712
Percent Change (as a percent) | 2.40% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 406 | 387
Percent Change (as a percent) | 4.70% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 323 | 324
Percent Change (as a percent) | (0.30%) |
MEDTECH | Surgery |  |
Sales by segment of business |  |
Sales to customers | $ 2,434 | 2,434
Percent Change (as a percent) | 0.00% |
MEDTECH | Surgery | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 975 | 921
Percent Change (as a percent) | 5.90% |
MEDTECH | Surgery | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,459 | 1,513
Percent Change (as a percent) | (3.60%) |
MEDTECH | Surgery | ADVANCED |  |
Sales by segment of business |  |
Sales to customers | $ 1,118 | 1,146
Percent Change (as a percent) | (2.50%) |
MEDTECH | Surgery | ADVANCED | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 444 | 417
Percent Change (as a percent) | 6.50% |
MEDTECH | Surgery | ADVANCED | International |  |
Sales by segment of business |  |
Sales to customers | $ 673 | 729
Percent Change (as a percent) | (7.60%) |
MEDTECH | Surgery | GENERAL |  |
Sales by segment of business |  |
Sales to customers | $ 1,316 | 1,288
Percent Change (as a percent) | 2.20% |
MEDTECH | Surgery | GENERAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 531 | 504
Percent Change (as a percent) | 5.40% |
MEDTECH | Surgery | GENERAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 785 | 784
Percent Change (as a percent) | 0.20% |
MEDTECH | Vision |  |
Sales by segment of business |  |
Sales to customers | $ 1,300 | 1,257
Percent Change (as a percent) | 3.40% |
MEDTECH | Vision | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 558 | 521
Percent Change (as a percent) | 7.10% |
MEDTECH | Vision | International |  |
Sales by segment of business |  |
Sales to customers | $ 743 | 736
Percent Change (as a percent) | 0.80% |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 953 | 910
Percent Change (as a percent) | 4.70% |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 444 | 400
Percent Change (as a percent) | 11.10% |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 509 | 511
Percent Change (as a percent) | (0.30%) |
MEDTECH | Vision | SURGICAL |  |
Sales by segment of business |  |
Sales to customers | $ 347 | 347
Percent Change (as a percent) | 0.10% |
MEDTECH | Vision | SURGICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 114 | 121
Percent Change (as a percent) | (6.00%) |
MEDTECH | Vision | SURGICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 233 | $ 226
Percent Change (as a percent) | 3.30% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherInterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |